Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02240810 · ClinicalTrials.gov registry record
PLATINUM Diversity
A clinical trial of Coronary Artery Disease and Atherosclerosis, sponsored by Boston Scientific Corporation.
- Completed
- Registry status
- 1,501
- Enrollment target
- 20
- Study locations
NCT02240810: Completed study of Coronary Artery Disease and Atherosclerosis, sponsored by Boston Scientific Corporation.
NCT02240810 is a study of Coronary Artery Disease and Atherosclerosis that has completed, run by Boston Scientific Corporation. The registered enrollment target is 1,501 participants, above the 1,280-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (17% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02240810, a study of Coronary Artery Disease and Atherosclerosis, has completed, sponsored by Boston Scientific Corporation.
- COMPLETED
- Registry status
- 1,501 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compile acute procedural performance and clinical outcomes data for the Promus PREMIER everolimus-eluting coronary stent system in understudied/underserved patient populations including women and minorities.
Primary Outcome
A Clinical Events Committee (CEC), independent group of physician experts was used to evaluate all reported cases of death, MI, TVR to determine whether they met the specific protocol definition of the event. It is the CEC adjudicated result that is used in the endpoint analysis. Results for the PROMUS Element Plus study are reported in record NCT01589978
Conditions Studied
Interventions
- DEVICE Percutaneous coronary intervention (Promus PREMIER)
Study Locations (20)
Florida
- Bay Area Cardiology - Brandon
- Research Physicians Network Alliance - Hollywood
- Memorial Hospital Jacksonville - Jacksonville
- Cardiovascular Institute of Northwest Florida - Panama City
- Charlotte Heart & Vascular - Port Charlotte
- Tallahassee Memorial Hospital - Tallahassee
- Pepin Heart Hospital and Dr. Kiran C. Patel Research Institute - Tampa
California
- Central Cardiology Medical Clinic - Bakersfield
- Sharp Chula Vista Medical Center - Chula Vista
- Cardiovascular Consultants Heart Center - Fresno
- UCLA Medical Center - Los Angeles
- Mercy General Hospital - Sacramento
Georgia
- Emory University - Atlanta
- University Hospital - Augusta
- Redmond Regional Medical Center - Rome
Arkansas
- St Bernards Heart and Vascular - Jonesboro
- Arkansas Cardiology/Baptist Health Medical Center - Little Rock
Arizona
- St Luke's Medical Center - Phoenix
District of Columbia
- Capital Research Institute - Washington D.C.
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,501 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-12 |
What the finished NCT02240810 record still lists
NCT02240810 is an observational study that tracks outcomes without assigning an intervention. Its 1,501 participants enrollment target places it among the larger protocols in the corpus, above the 1,280-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (17% higher).
The record links to 2 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Percutaneous coronary intervention (Promus PREMIER) is the first listed.
NCT02240810 names 20 study sites across 7 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT02240810 about?
NCT02240810 is a clinical study titled "PLATINUM Diversity". To compile acute procedural performance and clinical outcomes data for the Promus PREMIER everolimus-eluting coronary stent system in understudied/underserved patient populations including women and minorities.
What is the current status of trial NCT02240810?
This trial is currently completed. The enrollment target is 1,501 participants. The study started on 2014-10. Estimated completion is 2016-12.
What conditions does trial NCT02240810 study?
This clinical trial studies the following conditions: Coronary Artery Disease, Atherosclerosis.
What interventions are being tested in trial NCT02240810?
The interventions under investigation include: Percutaneous coronary intervention (Promus PREMIER) (DEVICE).
Who is sponsoring clinical trial NCT02240810?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02240810 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Coronary Artery Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02240810's enrollment target sits among peer trials
1,501 36th of 219 higher than 184 of 219 other Coronary Artery Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
RECRUITING · NA
-
MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions
RECRUITING · NA
-
PET/CT* vs. Cardiac CT for Detecting Coronary Atherosclerotic Disease [*PET: Positron Emission Tomography; CT: Computed Tomography]
RECRUITING · NA
-
Factors Affect Outcomes in Cardiovascular Surgery
RECRUITING
-
Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Change in Cardiovascular Health
RECRUITING · NA
-
Impact of Disclosing Coronary Artery Disease Polygenic Risk Score on Cardiovascular Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00178724 · 1,500 participants
Spinal Cord Injury Registry - North American Clinical Trials Network
- NCT00951366 · 1,500 participants
Preterm Lung Patient Registry
- NCT01050504 · 1,500 participants
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
- NCT02071134 · 1,500 participants
Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia